Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tristan Barber

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
International Journal of STD & AIDS|January 17, 2018
2016 United Kingdom national guideline on the sexual health care of men who have sex with menDan Clutterbuck, David Asboe, Tristan Barber, et al.
The Lancet. Healthy Longevity|May 15, 2026
Effectiveness of interventions on cognitive decline risk for people living with HIV on antiretroviral therapy: a systematic reviewRoopal Desai, Jaime Vera, Tristan Barber, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 16, 2014
Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trialAlan Winston, Janaki Amin, Amanda Clarke, et al.
Plos One|August 20, 2019
A need for implementation science to optimise the use of evidence-based interventions in HIV care: A systematic literature reviewJoseph Cox, Cassidy Gutner, Nadine Kronfli, et al.
Infectious Diseases and Therapy|August 24, 2021
HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature ReviewRickesh Patel, Lee Evitt, Ilias Mariolis, et al.
Vaccine|May 27, 2008
EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C aloneSheena McCormack, Wolfgang Stöhr, Tristan Barber, et al.
Vaccine|May 27, 2008
EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc ConsortiumPierre-Alexandre Bart, Ruth Goodall, Tristan Barber, et al.
The Journal of Experimental Medicine|January 16, 2008
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responsesAlexandre Harari, Pierre-Alexandre Bart, Wolfgang Stöhr, et al.
Plos One|April 21, 2017
Acceptability of an open-label wait-listed trial design: Experiences from the PROUD PrEP studyMitzy Gafos, Elizabeth Brodnicki, Monica Desai, et al.
Biorxiv : the Preprint Server for Biology|November 16, 2022
Attenuated humoral responses in HIV infection after SARS-CoV-2 vaccination are linked to global B cell defects and cellular immune profilesEmma Touizer, Aljawharah Alrubbayi, Rosemarie Ford, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
International Journal of STD & AIDS|January 17, 2018
2016 United Kingdom national guideline on the sexual health care of men who have sex with menDan Clutterbuck, David Asboe, Tristan Barber, et al.
The Lancet. Healthy Longevity|May 15, 2026
Effectiveness of interventions on cognitive decline risk for people living with HIV on antiretroviral therapy: a systematic reviewRoopal Desai, Jaime Vera, Tristan Barber, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 16, 2014
Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trialAlan Winston, Janaki Amin, Amanda Clarke, et al.
Plos One|August 20, 2019
A need for implementation science to optimise the use of evidence-based interventions in HIV care: A systematic literature reviewJoseph Cox, Cassidy Gutner, Nadine Kronfli, et al.
Infectious Diseases and Therapy|August 24, 2021
HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature ReviewRickesh Patel, Lee Evitt, Ilias Mariolis, et al.
Vaccine|May 27, 2008
EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C aloneSheena McCormack, Wolfgang Stöhr, Tristan Barber, et al.
Vaccine|May 27, 2008
EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc ConsortiumPierre-Alexandre Bart, Ruth Goodall, Tristan Barber, et al.
The Journal of Experimental Medicine|January 16, 2008
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responsesAlexandre Harari, Pierre-Alexandre Bart, Wolfgang Stöhr, et al.
Plos One|April 21, 2017
Acceptability of an open-label wait-listed trial design: Experiences from the PROUD PrEP studyMitzy Gafos, Elizabeth Brodnicki, Monica Desai, et al.
Biorxiv : the Preprint Server for Biology|November 16, 2022
Attenuated humoral responses in HIV infection after SARS-CoV-2 vaccination are linked to global B cell defects and cellular immune profilesEmma Touizer, Aljawharah Alrubbayi, Rosemarie Ford, et al.
Pageof 2